Bristol Myers meets some diversity goals early, while missing others
Bristol Myers Squibb has met some of its big health equity goals early, while missing two internal goals focused on diversifying its workforce. Now, the company says it’s setting the bar a little higher.
Bristol Myers announced on Wednesday that roughly 58% of its clinical trial sites are now located in ethnically diverse areas, surpassing its initial goal of 25%. The news comes as the pandemic casts a harsh spotlight on the lack of diversity in clinical trials. Of the 53 drugs approved in 2020, Black patients represented just about 8% of trial participants that regulators based their decisions on, and Hispanic patients represented just over 12.6%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.